{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T09:43:43Z","timestamp":1777715023087,"version":"3.51.4"},"reference-count":27,"publisher":"Impact Journals, LLC","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2021,7,6]]},"DOI":"10.18632\/oncotarget.27960","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T15:28:43Z","timestamp":1625585323000},"page":"1434-1441","source":"Crossref","is-referenced-by-count":11,"title":["A Dynamic Energy Budget (DEB) based modeling framework to describe tumor-in-host growth inhibition and cachexia onset during anticancer treatment in <i>in vivo<\/i> xenograft studies"],"prefix":"10.18632","volume":"12","author":[{"given":"Elena Maria","family":"Tosca","sequence":"first","affiliation":[{"name":"Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, I-27100, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Rocchetti","sequence":"additional","affiliation":[{"name":"Consultant, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Magni","sequence":"additional","affiliation":[{"name":"Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, I-27100, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","article-title":"Understanding the mechanisms and treatment options in cancer cachexia","volume":"1","author":"Baracos","year":"2013","journal-title":"Nature Reviews Clinical Oncology"},{"key":"2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"1","author":"Baracos","year":"2011","journal-title":"Lancet Oncol"},{"key":"3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: mediators, signaling, and metabolic pathways","volume":"1","author":"Guttridge","year":"2012","journal-title":"Cell Metab"},{"key":"4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.critrevonc.2017.06.008","article-title":"Overcoming obstacles in the design of cancer anorexia\/weight loss trials","volume":"11","author":"Jatoi","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.semcdb.2015.09.002","article-title":"Experimental cancer cachexia: Evolving strategies for getting closer to the human scenario","volume":"5","author":"s","year":"2016","journal-title":"Semin Cell Dev Biol"},{"key":"6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/SPC.0000000000000233","article-title":"Animal models for cancer cachexia","volume":"1","author":"Penna","year":"2016","journal-title":"Curr Opin Support Palliat Care"},{"key":"7","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/17460441.2020.1724954","article-title":"Promising models for cancer-induced cachexia drug discovery","volume":"1","author":"Springer","year":"2020","journal-title":"Expert Opin Drug Discov"},{"key":"8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrclinonc.2018.14","article-title":"Bridging the gap: are animal models consistent with clinical cancer cachexia?","volume":"1","author":"Baracos","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"9","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1097\/MPA.0000000000001124","article-title":"Pancreatic Cancer-Induced Cachexia and Relevant Mouse Models","volume":"4","author":"Mace","year":"2018","journal-title":"Pancreas"},{"key":"10","unstructured":"Kooijman. Dynamic energy budgets in biological systems. Cambridge university press. 1993."},{"key":"11","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1038\/sj.bjc.6601394","article-title":"The embedded tumour: host physiology is important for the evaluation of tumour growth","volume":"8","author":"Kooijman","year":"2003","journal-title":"Br J Cancer"},{"key":"12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1023\/a:1021336321551","article-title":"A mathematical model that accounts for the effects of caloric restriction on body weight and longevity","volume":"3","author":"Kooijman","year":"2002","journal-title":"Biogerontology"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Liotta. Influence of Tumor Development on the Host. Kluwer Academic Publishers. Cancer Growth Progress. 1989.","DOI":"10.1007\/978-94-009-2528-1"},{"key":"14","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1158\/0008-5472.CAN-19-0811","article-title":"A Tumor-in-Host DEB-Based Approach for Modeling Cachexia and Bevacizumab Resistance","volume":"8","author":"Magni","year":"2020","journal-title":"Cancer Res"},{"key":"15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11095-019-2568-9","article-title":"A Population Dynamic Energy Budget-Based Tumor Growth Inhibition Model for Etoposide Effects on Wistar Rats","volume":"3","author":"Magni","year":"2019","journal-title":"Pharm Res"},{"key":"16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jtbi.2018.04.012","article-title":"Modeling tumor growth inhibition and toxicity outcome after administration of anticancer agents in xenograft mice: A Dynamic Energy Budget (DEB) approach","volume":"45","author":"Magni","year":"2018","journal-title":"J Theor Biol"},{"key":"17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5487\/TR.2014.30.1.001","article-title":"Human tumor xenograft models for preclinical assessment of anticancer drug development","volume":"3","author":"Jung","year":"2014","journal-title":"Toxicol Res"},{"key":"18","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1158\/0008-5472.CAN-05-3627","article-title":"Contributions of human tumor xenografts to anticancer drug development","volume":"6","author":"Burger","year":"2006","journal-title":"Cancer Res"},{"key":"19","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1109\/TBME.2008.913420","article-title":"A minimal model of tumor growth inhibition","volume":"5","author":"Rocchetti","year":"2008","journal-title":"IEEE Trans Biomed Eng"},{"key":"20","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1158\/0008-5472.can-03-2524","article-title":"Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents","volume":"6","author":"Rocchetti","year":"2004","journal-title":"Cancer Res"},{"key":"21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.mbs.2005.12.028","article-title":"A mathematical model to study the effects of drugs administration on tumor growth dynamics","volume":"20","author":"Nicolao","year":"2006","journal-title":"Math Biosci"},{"key":"22","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1109\/TBME.2012.2197680","article-title":"A minimal model of tumor growth inhibition in combination regimens under the hypothesis of no interaction between drugs","volume":"5","author":"Nicolao","year":"2012","journal-title":"IEEE Trans Biomed Eng"},{"key":"23","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/aps.2016.55","article-title":"Preclinical PK\/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice","volume":"3","author":"Zhou","year":"2016","journal-title":"Acta Pharmacol Sin"},{"key":"24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10928-009-9117-9","article-title":"Modeling of tumor growth and anticancer effects of combination therapy","volume":"3","author":"Schropp","year":"2009","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"25","unstructured":"Gauderat, Fouliard, Chenel. Reversing resistance to anticancer treatment supported by pharmacokinetic\/pharmacodynamic modeling of tumor growth kinetics in xenograft mice. In: PAGE 27. 2018. Available from: https:\/\/www.page-meeting.org\/?abstract=8466."},{"key":"26","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/(sici)1096-9098(199708)65:4<284::aid-jso11>3.0.co;2-2","article-title":"On the growth rates of human malignant tumors: implications for medical decision making","volume":"6","author":"Mattson","year":"1997","journal-title":"J Surg Oncol"},{"key":"27","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nrc2627","article-title":"Parallel progression of primary tumours and metastases","volume":"9","author":"Klein","year":"2009","journal-title":"Nat Rev Cancer"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27960","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T15:28:50Z","timestamp":1625585330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":27,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2021,7,6]]}},"alternative-id":["27960"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.27960","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,6]]}}}